GRPH News and Press, Graphite Bio Inc. From 06/30/21

Brian Ach/Getty Images Entertainment Intellia Therapeutics ([[NTLA]] +7.7%) has gained more than 80.0% since the company joined Gilead Sciences ([[GILD]] +1.2%) over the weekend to unveil the first first-ever clinical data to support the safety and efficacy of in-vivo CRISPR genome editi...

Andy/iStock via Getty Images The strength of gene-editing space has benefited even the recently IPO’ed companies in the subsector even though their assets have yet to reach the clinical stage. The rally began after Intellia and Regeneron disclosed interim results from a Phase 1 trial f...

16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity, which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social networking platform Soulgate. The largest deal o...

Andy/iStock via Getty Images Gene editing firm Graphite Bio ([[GRPH]]) Jumped above the IPO price on Friday in its first trading session following an upsized IPO priced at $17.00 per share. Shares opened at $22.01 at about 11:55 AM ET, up 30.0% from the initial public offering’s price ...

Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a pric...

NEW YORK , June 6, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Designations for th...